Positron Corp. (POSC) soars on news of $38 million bonds award
Posted on: September 21st, 2011Written by:
Molecular imaging company, Positron Corp. (OTCBB: POSC) was up more than 49 percent in mid-day trading on Wednesday, after the company announced that the Indiana Finance Authority approved its $38 million Midwestern Disaster Area Bond volume cap application.
Shares of Positron touched a daily high of $0.029, in mid-day trading on Wednesday, up from Tuesday’s closing price of $0.0181.
According to a September 21 press release, the bonds will be a part of an overall long-term strategic investment Positron is making in its proposed high energy 70 MeV cyclotron project and radiopharmaceutical manufacturing facility in Noblesville, Indiana.
Positron is a molecular imaging company focused on Nuclear Cardiology. Positron provides innovative molecular technologies and services that are reshaping the field of nuclear cardiology through proprietary PET imaging and radiopharmaceutical solutions with a strong commitment to advancing the practice and technology of nuclear medicine.
Caduceus Software Systems Corp. (CSOC) soars on pricey marketing campaign
Posted on: September 19th, 2011Written by:
Software medical records management software developer, Caduceus Software Systems Corp. (OTCBB:CSOC) traded more than 16 million shares on Monday, a far cry from the company’s average three-month volume of 49,478 shares, after the onset of a $1 million-plus e-mail campaign spearheaded by VictoryStocks.com.
The campaign was paid for by a third party, listed as “Firdaus Inc.”
The last time Caduceus Software Systems Corp. issued a press release was about a month ago, when the Birmingham, England-based company announced its goals and mission statement.
The Company has the primary goal of providing good valuable medical records management software (MMS) to medical professionals. The Company’s target market is to provide Electronic Health Records (EHR) management for practitioners and physicians, and combine it with the appointment scheduling tools useful for medical office assistants. While some software caters to specifically to doctors and some software caters specifically to their supporting staff, Caduceus MMS integrates these tasks together in a single software solution, the August 16 press release stated.
“The recent news of the American health care reform and the cost of health care in Canada and United States warrant better software to manage the flow of patient information and fast and accurate billing,” sais Derrick Gidden, President of Caduceus Software Systems Corp in the August 16 press release. “The Canadian and American markets are vast and total more than 800,000 private physicians and practitioners. From the news studies, we feel that many of these medical professionals could benefit from our software in terms of our price point, multiple languages, tech support, and platform compatibility requirements.”
For the three months ended June 30, Caduceus Software Systems Corp. reported $0 revenue, and a net loss of $4.9 million.
Generex Biotechnology Corp. (GNBT) spins out, stock points higher
Posted on: September 15th, 2011Written by:
Generex Biotechnology Corp. (OTCBB: GNBT) saw its shares gain 8.7% to 9.89 cents, as Thursday’s markets closed, on news of the spinout of one of its subsidiaries. Volume for the stock was 1.3 million shares, nosing out its full-day average.
A news release dated Sept. 15 announced that the company, based in Worcester, Mass., provided an update on the status of the previously announced spinout of its wholly-owned subsidiary, Antigen Express, Inc.
The Company is in the midst of a detailed and comprehensive review of several transaction opportunities, including both shell companies and operating biotech companies with synergistic intellectual properties, in each case Securities and Exchange Commission registrants and Depository Trust Company eligible companies, into which Antigen Express will be merged.
Generex CEO Mark Fletcher, “We are undertaking our due diligence examination of available alternatives with a view to identifying an appropriate transaction for the Antigen Express spinout.
“We will proceed with expedition to negotiate an agreement with the target company, complete the merger of Antigen Express into that company, and conduct an initial fund raising. If the merger and the initial fund raising are successful, we will then seek a listing of the merged company’s stock on a national stock exchange.”
Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies.
Phototron Holdings (PHOT) boosts sales, stock leaps
Posted on: September 15th, 2011Written by:
Phototron Holdings (OTCBB: PHOT) shares climbed 138.5% to 31 cents on word of exciting sales figures. Volume for the stock topped 25,000, or at least double its all-day average.
A news release put out Sept. 7 revealed that the company had increased sales by more than 78% during August, entering the second month of its new direct selling business model. August’s strong performance represented $107,000 of unaudited sales compared to approximately $60,000 of unaudited sales in July.
Phototron’s new direct selling business model will help expand Phototron’s future sales capabilities to harness the untapped demand for its innovative turn-key hydroponic gardening system.
The same release quoted CEO Doug Braun thus: “We are extremely pleased with Phototron’s results in our second full month after implementing our new business model and strategic growth initiatives.
“Significant increases in both sales and Phototron’s new affiliates demonstrate that our product and business opportunity are attractive to our target audience. In transition periods, it typically takes time to gather momentum. Now that Phototron is starting to see positive results we are confident that we will continue to see accelerated growth as we begin to focus our energies on leveraging our exciting products and new business model to consumers across the US and worldwide.”
The new direct sales model, initiated in June, represents Phototron’s new direct sales initiatives, which are expected to serve both the $30-billion home gardening market and the $1.7-billion medical marijuana community.
Phototron Holdings, Inc., based in Woodland Hills, Calif., designs and manufactures cutting-edge indoor mini-greenhouses capable of growing herbs, vegetables, flowers, fruits and terrestrial plants stronger and faster than traditional farming methods.
Bioheart Inc. (BHRT) has breakout day over FDA OK
Posted on: September 14th, 2011Written by:
Bioheart Inc. (OTCBB: BHRT) leaped 15.3% to 8.3 cents Wednesday on word of a clinical program the company was engaging in, using adipose cells. Volume for the stock topped 8.1 million near Wednesday’s close.
A news release issued Sept. 14 declared that the company out of Sunrise, Florida announced that they will begin a U.S. clinical program called the ANGEL trial utilizing adipose derived cells or LipiCell for congestive heart failure patients. Using the clinical data from a Phase I/II trial in Mexico and preclinical studies, Bioheart will apply to the Food and Drug Administration (FDA) to begin a Phase I study in the US.
In collaboration with the Regenerative Medicine Institute of Tijuana, Mexico, six congestive heart failure patients have been successfully treated in a Phase I/II trial at Hospital Angeles Tijuana.
The therapy involves the use of stem cells derived from the patient’s own fat (adipose tissue) obtained using liposuction. These patients have demonstrated on average, an absolute improvement of 13 percentage points in ejection fraction and an increase of 100 meters in their six-minute walk distance.
The U.S. ANGEL trial design and results from the Mexico trial were presented by Bioheart’s Chief Scientific Officer, Kristin Comella at the Stem Cells USA & Regenerative Medicine Congress in Boston this week. She was quoted in the same release as saying, “Safety and efficacy have been successfully demonstrated in the trial at Hospital Angeles and we are looking forward to beginning one of the first U.S. trials using adipose derived cells for congestive heart failure patients.”
Bioheart is committed to maintaining our leading position within the cardiovascular sector of the cell technology industry delivering cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues.
Coldwater Creek Inc. (CWTR) shares vault on CEO stock buy
Posted on: September 14th, 2011Written by:
Coldwater Creek Inc. (Nasdaq: CWTR) shares spiked 14.8% to $1.63 Wednesday approaching noon ET, on news Tuesday of a stock purchase by its CEO. Volume for the stock topped two million shares, compared to an all-day average of 887,000.
An article posted Sept. 13 on the site Seeking Alpha mentioned that in recent days Dennis Ponce purchased over 600,000 shares at an average price of around 90 cents. The story also said pointed out that Coldwater Creek has seen quarterly net sales decrease to $181.4 million compared to $253 million in the same quarter in 2010.
Gross profit margins tightened for the quarter as well. Gross profit came in at $45.3 million for the quarter or 25% of net sales, compared with $84.7 million, or 33.4% of net sales in the same quarter in 2010.
The piece in Seeking Alpha added the company recently announced a three-part plan to turn it around, the key elements of which consist of a comprehensive brand marketing campaign, retail store optimization and a merchandising revitalization plan.
Coldwater Creek is a leading specialty retailer of women’s apparel, gifts, jewelry, and accessories founded in 1984 and headquartered in Sandpoint, Idaho.
